Conatus Pharmaceuticals Reports First Quarter 2014 Financial Results and Program Updates
GlobeNewswire - 2 hrs 54 mins ago
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2014, and provided updates on its clinical development programs.
Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients
GlobeNewswire - Mon May 12, 6:01AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant (POLT) recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR).
Global Liver Transplantation Therapeutics Pipeline Review 2014 - Analysis of 6 Companes & 9 Drug Profiles
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/czlhvb/liver) has announced the addition of the "Liver Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Astellas Pharma Inc. - Veloxis Pharmaceuticals A/S - Digna Biotech, S.L. - Conatus Pharmaceuticals Inc. - REPLICor Inc. - Dompe Farmaceutici S.p.A. Drug Profiles - tacrolimus ER - melatonin - reparixin - emricasan - tacrolimus - Regulatory T Cell Therapy For Liver Transplantation - Umbilical Cord Mesenchymal Stem Cell Transplantation - cardiotrophin-1 - REP-9-AC For more information visit http://www.researchandmarkets.com/research/czlhvb/liver
Conatus Pharmaceuticals to Report First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31, 2014, after the market close on Tuesday, May 13, 2014. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 13, 2014, to discuss the financial results and provide a corporate update.
Conatus Pharmaceuticals to Present at Deutsche Bank Health Care Conference
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Deutsche Bank 39 Annual Health Care Conference at 2:50 p.m. ET on Wednesday, May 7, 2014, in Boston.
Global Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2014 - Analysis of 24 Companies & 31 Drug Profiles
M2 - Mon Apr 28, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7dwrzr/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Novo Nordisk A/S - Mochida Pharmaceutical Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Genfit SA - Orchid Chemicals & Pharmaceuticals Ltd - La Jolla Pharmaceutical Company - ProMetic Life Sciences Inc. - Immuron Limited - Phenex Pharmaceuticals AG - Wellstat Therapeutics Corporation - Zafgen Inc. - Conatus Pharmaceuticals Inc. - Intercept Pharmaceuticals, Inc. - Obio Pharmaceutical Holdings Limited - Tobira Therapeutics, Inc. - Jenken Biosciences, Inc - Kyorin Pharmaceutical Co., Ltd. - NasVax Ltd. - Stelic Institute & Co. - Galmed International Ltd. - Connexios Life Sciences Pvt. Ltd. - Kadmon Pharmaceuticals, LLC Drug Profiles - GFT-505 - KD-025 - obeticholic acid - liraglutide - Aramchol - emricasan - atorvastatin calcium - Anti-CD3 Oral Immunotherapy - IMM-124E - Px-102 - icosapent ethyl - BLX-1002 - tranilast - Px-104 - tipelukast - GR-MD-02 - GCS-100 - cenicriviroc - PN-2XXX - JKB-121 - JKB-119 - AK-20 - PBI-4050 - CNXFC-010 - ISIS-DGAT2Rx - ZGN-839 - remogliflozin etabonate - Small Molecule to Inhibit SCD-1 for NASH - Px-103 - STNM-09 For more information visit http://www.researchandmarkets.com/research/7d...nalcoholic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks
at The Street - Wed Apr 09, 9:06AM CDT
Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.
Company news for March 31, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 9:06AM CDT
Companies in the News are: FINL,RH,CNAT,PRGS
Conatus Pharmaceuticals Reports 2013 Financial Results and Program Updates
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the fourth quarter and full year ended December 31, 2013, and provided updates on its clinical development programs.
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2013, after the market close on Thursday, March 27, 2014. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Thursday, March 27, 2014, to discuss the financial results and provide a corporate update.
3 Reasons Potential Side Effects Trump Positive Phase 3 Data
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 17, 4:47PM CDT
In its 10-K on Friday, Intercept disclosed that patients with nonalcoholic steatohepatitis, or NASH, taking its liver drug obeticholic acid, or OCA experienced cardiovascular serious adverse events. On Sunday, the biotech followed up with...
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus
PR Newswire - Thu Mar 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), GW Pharmaceuticals plc (NASDAQ: GWPH), Galena Biopharma, Inc. (NASDAQ: GALE), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial
GlobeNewswire - Mon Mar 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan, in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoholic steatohepatitis (NASH).
4 Big-Volume Stocks to Trade for Breakouts
at The Street - Thu Feb 27, 5:00AM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
Conatus Pharmaceuticals to Participate in Upcoming Investor Events
GlobeNewswire - Thu Feb 20, 6:00AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled participation in the following investor events in February:
Conatus Pharmaceuticals (CNAT) Soars: Stock Rises 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:39AM CST
Conatus Pharmaceuticals Inc. was a big mover last session, as its shares rose over 19% on the day.
Conatus Pharmaceuticals Appoints Two Additional Independent Board Members
GlobeNewswire - Mon Feb 10, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of two additional independent members to the Conatus Board of Directors: Daniel L. Kisner, M.D., a highly respected life sciences leader with demonstrated successes in drug development, pharmaceutical and research tool approvals, and venture capital investments; and Preston S. Klassen, M.D., M.H.S., an accomplished biopharmaceutical company executive with broad experience including clinical, regulatory, medical affairs and commercial responsibilities across multiple therapeutic areas.
Conatus Pharmaceuticals to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference at 1:00 p.m. ET on Monday, February 10, 2014, in New York.
Healthcare Companies Report Petition Submission, Pricing of Follow-On Offerings and Stock Price Movements - Research Report on Johnson & Johnson, GW Pharma, Conatus Pharma, Chelsea, and Insmed
PR Newswire - Tue Jan 14, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.